Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.08/23/2018

Source: Kidney Cancer Association - August 23, 2018 Category: Urology & Nephrology Source Type: news